Prescription Patterns of Mycophenolate Mofetil in a Group of Patients from Colombia
Mycophenolate mofetil is used for the prevention of solid organ transplant rejection and for other indications, such as systemic lupus erythematosus (SLE). To determine the prescription patterns of mycophenolate mofetil in a group of Colombian patients. This was a cross-sectional study of patients r...
Gespeichert in:
| Veröffentlicht in: | Healthcare (Basel) 2024-11, Vol.12 (22), p.2224 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 22 |
| container_start_page | 2224 |
| container_title | Healthcare (Basel) |
| container_volume | 12 |
| creator | Machado-Duque, Manuel Enrique Gaviria-Mendoza, Andrés Valladales-Restrepo, Luis Fernando Vallejos-Narváez, Álvaro Piragauta-Vargas, Natalia Machado-Alba, Jorge Enrique |
| description | Mycophenolate mofetil is used for the prevention of solid organ transplant rejection and for other indications, such as systemic lupus erythematosus (SLE).
To determine the prescription patterns of mycophenolate mofetil in a group of Colombian patients.
This was a cross-sectional study of patients receiving mycophenolate mofetil between 2021 and 2022. The data were obtained from a drug dispensing database. Sociodemographic, clinical (diagnostic), and pharmacological variables were identified.
A total of 979 patients who underwent treatment were identified; their mean age was 45.9 ± 17.1 years, and 87.4% were women. The main diagnosis associated with the use of mycophenolate mofetil was SLE (39.1%), followed by other rheumatic diseases (8.5%), nephrotic syndrome (7.5%), and solid organ transplantation (6.4%). The relationship between the mean dose and the defined daily dose was 0.75. Ten percent of patients received mycophenolate alone, whereas 32.9% received mycophenolate in combination therapy with conventional disease-modifying antirheumatic drugs and glucocorticoids. A total of 76.2% had polypharmacy (five or more drugs).
Mycophenolate mofetil is used mainly in combination therapy for patients with SLE and other rheumatological diseases and for solid organ transplants at doses lower than those recommended. |
| doi_str_mv | 10.3390/healthcare12222224 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11593479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A818200668</galeid><sourcerecordid>A818200668</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-aa8517109c1d29e8096b9eec40a525d0f1b827ad708b5fb0d49c1706cda832213</originalsourceid><addsrcrecordid>eNptkk1vFSEUhonR2Kb2D7gwJG7c3MrHcAdWprmx1aSNTaprwjCHXhoGRmBM-u_LtbW22sPiEHjel49zEHpLyRHninzcggl1a00Gyn5H9wLtt9SvFOHs5aP5Hjos5Zq0UJRLLl6jPa6EEh1j--jyIkOx2c_Vp4gvTK2QY8HJ4fMbm-YtxBRMBXyeHFQfsI_Y4NOclnnHNN5DrAW7nCa8SSFNgzdv0CtnQoHD-3yAfpx8_r75sjr7dvp1c3y2srxXdWWMFLSnRFk6MgWSqPWgAGxHjGBiJI4OkvVm7IkchBvI2DWyJ2s7GskZo_wAfbrznZdhgtG2m2QT9Jz9ZPKNTsbrpzvRb_VV-qUpFYp3vWoOH-4dcvq5QKl68sVCCCZCWormlPOOSsm7hr7_B71OS47tfTuKKdEqwP9SVyaA9tGldrDdmepjSSUjZL2WjTp6hmpjhMnbFMH5tv5EwO4ENqdSMriHR1Kid-2g_2-HJnr3-HseJH-Kz28BsFyxhQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3132952243</pqid></control><display><type>article</type><title>Prescription Patterns of Mycophenolate Mofetil in a Group of Patients from Colombia</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Machado-Duque, Manuel Enrique ; Gaviria-Mendoza, Andrés ; Valladales-Restrepo, Luis Fernando ; Vallejos-Narváez, Álvaro ; Piragauta-Vargas, Natalia ; Machado-Alba, Jorge Enrique</creator><creatorcontrib>Machado-Duque, Manuel Enrique ; Gaviria-Mendoza, Andrés ; Valladales-Restrepo, Luis Fernando ; Vallejos-Narváez, Álvaro ; Piragauta-Vargas, Natalia ; Machado-Alba, Jorge Enrique</creatorcontrib><description>Mycophenolate mofetil is used for the prevention of solid organ transplant rejection and for other indications, such as systemic lupus erythematosus (SLE).
To determine the prescription patterns of mycophenolate mofetil in a group of Colombian patients.
This was a cross-sectional study of patients receiving mycophenolate mofetil between 2021 and 2022. The data were obtained from a drug dispensing database. Sociodemographic, clinical (diagnostic), and pharmacological variables were identified.
A total of 979 patients who underwent treatment were identified; their mean age was 45.9 ± 17.1 years, and 87.4% were women. The main diagnosis associated with the use of mycophenolate mofetil was SLE (39.1%), followed by other rheumatic diseases (8.5%), nephrotic syndrome (7.5%), and solid organ transplantation (6.4%). The relationship between the mean dose and the defined daily dose was 0.75. Ten percent of patients received mycophenolate alone, whereas 32.9% received mycophenolate in combination therapy with conventional disease-modifying antirheumatic drugs and glucocorticoids. A total of 76.2% had polypharmacy (five or more drugs).
Mycophenolate mofetil is used mainly in combination therapy for patients with SLE and other rheumatological diseases and for solid organ transplants at doses lower than those recommended.</description><identifier>ISSN: 2227-9032</identifier><identifier>EISSN: 2227-9032</identifier><identifier>DOI: 10.3390/healthcare12222224</identifier><identifier>PMID: 39595422</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antirheumatic agents ; Autoimmune diseases ; B cells ; Bioethics ; Care and treatment ; Disease prevention ; Dosage and administration ; Drug dosages ; Drug therapy ; Drugs ; FDA approval ; Hepatitis ; Kidney diseases ; Lipids ; Lupus ; Medical research ; Medicine, Experimental ; Metabolism ; Mycophenolate mofetil ; Nonsteroidal anti-inflammatory drugs ; Pharmacy ; Prescribing ; Prescription drugs ; Rheumatic diseases ; Sociodemographics ; Systemic lupus erythematosus ; Transplantation of organs, tissues, etc ; Transplants & implants</subject><ispartof>Healthcare (Basel), 2024-11, Vol.12 (22), p.2224</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c379t-aa8517109c1d29e8096b9eec40a525d0f1b827ad708b5fb0d49c1706cda832213</cites><orcidid>0000-0003-2500-7658 ; 0000-0002-8455-0936 ; 0000-0003-0069-7920 ; 0000-0002-4245-0101</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593479/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593479/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39595422$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Machado-Duque, Manuel Enrique</creatorcontrib><creatorcontrib>Gaviria-Mendoza, Andrés</creatorcontrib><creatorcontrib>Valladales-Restrepo, Luis Fernando</creatorcontrib><creatorcontrib>Vallejos-Narváez, Álvaro</creatorcontrib><creatorcontrib>Piragauta-Vargas, Natalia</creatorcontrib><creatorcontrib>Machado-Alba, Jorge Enrique</creatorcontrib><title>Prescription Patterns of Mycophenolate Mofetil in a Group of Patients from Colombia</title><title>Healthcare (Basel)</title><addtitle>Healthcare (Basel)</addtitle><description>Mycophenolate mofetil is used for the prevention of solid organ transplant rejection and for other indications, such as systemic lupus erythematosus (SLE).
To determine the prescription patterns of mycophenolate mofetil in a group of Colombian patients.
This was a cross-sectional study of patients receiving mycophenolate mofetil between 2021 and 2022. The data were obtained from a drug dispensing database. Sociodemographic, clinical (diagnostic), and pharmacological variables were identified.
A total of 979 patients who underwent treatment were identified; their mean age was 45.9 ± 17.1 years, and 87.4% were women. The main diagnosis associated with the use of mycophenolate mofetil was SLE (39.1%), followed by other rheumatic diseases (8.5%), nephrotic syndrome (7.5%), and solid organ transplantation (6.4%). The relationship between the mean dose and the defined daily dose was 0.75. Ten percent of patients received mycophenolate alone, whereas 32.9% received mycophenolate in combination therapy with conventional disease-modifying antirheumatic drugs and glucocorticoids. A total of 76.2% had polypharmacy (five or more drugs).
Mycophenolate mofetil is used mainly in combination therapy for patients with SLE and other rheumatological diseases and for solid organ transplants at doses lower than those recommended.</description><subject>Antirheumatic agents</subject><subject>Autoimmune diseases</subject><subject>B cells</subject><subject>Bioethics</subject><subject>Care and treatment</subject><subject>Disease prevention</subject><subject>Dosage and administration</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>FDA approval</subject><subject>Hepatitis</subject><subject>Kidney diseases</subject><subject>Lipids</subject><subject>Lupus</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Metabolism</subject><subject>Mycophenolate mofetil</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Pharmacy</subject><subject>Prescribing</subject><subject>Prescription drugs</subject><subject>Rheumatic diseases</subject><subject>Sociodemographics</subject><subject>Systemic lupus erythematosus</subject><subject>Transplantation of organs, tissues, etc</subject><subject>Transplants & implants</subject><issn>2227-9032</issn><issn>2227-9032</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1vFSEUhonR2Kb2D7gwJG7c3MrHcAdWprmx1aSNTaprwjCHXhoGRmBM-u_LtbW22sPiEHjel49zEHpLyRHninzcggl1a00Gyn5H9wLtt9SvFOHs5aP5Hjos5Zq0UJRLLl6jPa6EEh1j--jyIkOx2c_Vp4gvTK2QY8HJ4fMbm-YtxBRMBXyeHFQfsI_Y4NOclnnHNN5DrAW7nCa8SSFNgzdv0CtnQoHD-3yAfpx8_r75sjr7dvp1c3y2srxXdWWMFLSnRFk6MgWSqPWgAGxHjGBiJI4OkvVm7IkchBvI2DWyJ2s7GskZo_wAfbrznZdhgtG2m2QT9Jz9ZPKNTsbrpzvRb_VV-qUpFYp3vWoOH-4dcvq5QKl68sVCCCZCWormlPOOSsm7hr7_B71OS47tfTuKKdEqwP9SVyaA9tGldrDdmepjSSUjZL2WjTp6hmpjhMnbFMH5tv5EwO4ENqdSMriHR1Kid-2g_2-HJnr3-HseJH-Kz28BsFyxhQ</recordid><startdate>20241107</startdate><enddate>20241107</enddate><creator>Machado-Duque, Manuel Enrique</creator><creator>Gaviria-Mendoza, Andrés</creator><creator>Valladales-Restrepo, Luis Fernando</creator><creator>Vallejos-Narváez, Álvaro</creator><creator>Piragauta-Vargas, Natalia</creator><creator>Machado-Alba, Jorge Enrique</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2500-7658</orcidid><orcidid>https://orcid.org/0000-0002-8455-0936</orcidid><orcidid>https://orcid.org/0000-0003-0069-7920</orcidid><orcidid>https://orcid.org/0000-0002-4245-0101</orcidid></search><sort><creationdate>20241107</creationdate><title>Prescription Patterns of Mycophenolate Mofetil in a Group of Patients from Colombia</title><author>Machado-Duque, Manuel Enrique ; Gaviria-Mendoza, Andrés ; Valladales-Restrepo, Luis Fernando ; Vallejos-Narváez, Álvaro ; Piragauta-Vargas, Natalia ; Machado-Alba, Jorge Enrique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-aa8517109c1d29e8096b9eec40a525d0f1b827ad708b5fb0d49c1706cda832213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antirheumatic agents</topic><topic>Autoimmune diseases</topic><topic>B cells</topic><topic>Bioethics</topic><topic>Care and treatment</topic><topic>Disease prevention</topic><topic>Dosage and administration</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>FDA approval</topic><topic>Hepatitis</topic><topic>Kidney diseases</topic><topic>Lipids</topic><topic>Lupus</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Metabolism</topic><topic>Mycophenolate mofetil</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Pharmacy</topic><topic>Prescribing</topic><topic>Prescription drugs</topic><topic>Rheumatic diseases</topic><topic>Sociodemographics</topic><topic>Systemic lupus erythematosus</topic><topic>Transplantation of organs, tissues, etc</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Machado-Duque, Manuel Enrique</creatorcontrib><creatorcontrib>Gaviria-Mendoza, Andrés</creatorcontrib><creatorcontrib>Valladales-Restrepo, Luis Fernando</creatorcontrib><creatorcontrib>Vallejos-Narváez, Álvaro</creatorcontrib><creatorcontrib>Piragauta-Vargas, Natalia</creatorcontrib><creatorcontrib>Machado-Alba, Jorge Enrique</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Healthcare (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Machado-Duque, Manuel Enrique</au><au>Gaviria-Mendoza, Andrés</au><au>Valladales-Restrepo, Luis Fernando</au><au>Vallejos-Narváez, Álvaro</au><au>Piragauta-Vargas, Natalia</au><au>Machado-Alba, Jorge Enrique</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prescription Patterns of Mycophenolate Mofetil in a Group of Patients from Colombia</atitle><jtitle>Healthcare (Basel)</jtitle><addtitle>Healthcare (Basel)</addtitle><date>2024-11-07</date><risdate>2024</risdate><volume>12</volume><issue>22</issue><spage>2224</spage><pages>2224-</pages><issn>2227-9032</issn><eissn>2227-9032</eissn><abstract>Mycophenolate mofetil is used for the prevention of solid organ transplant rejection and for other indications, such as systemic lupus erythematosus (SLE).
To determine the prescription patterns of mycophenolate mofetil in a group of Colombian patients.
This was a cross-sectional study of patients receiving mycophenolate mofetil between 2021 and 2022. The data were obtained from a drug dispensing database. Sociodemographic, clinical (diagnostic), and pharmacological variables were identified.
A total of 979 patients who underwent treatment were identified; their mean age was 45.9 ± 17.1 years, and 87.4% were women. The main diagnosis associated with the use of mycophenolate mofetil was SLE (39.1%), followed by other rheumatic diseases (8.5%), nephrotic syndrome (7.5%), and solid organ transplantation (6.4%). The relationship between the mean dose and the defined daily dose was 0.75. Ten percent of patients received mycophenolate alone, whereas 32.9% received mycophenolate in combination therapy with conventional disease-modifying antirheumatic drugs and glucocorticoids. A total of 76.2% had polypharmacy (five or more drugs).
Mycophenolate mofetil is used mainly in combination therapy for patients with SLE and other rheumatological diseases and for solid organ transplants at doses lower than those recommended.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39595422</pmid><doi>10.3390/healthcare12222224</doi><orcidid>https://orcid.org/0000-0003-2500-7658</orcidid><orcidid>https://orcid.org/0000-0002-8455-0936</orcidid><orcidid>https://orcid.org/0000-0003-0069-7920</orcidid><orcidid>https://orcid.org/0000-0002-4245-0101</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2227-9032 |
| ispartof | Healthcare (Basel), 2024-11, Vol.12 (22), p.2224 |
| issn | 2227-9032 2227-9032 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11593479 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Antirheumatic agents Autoimmune diseases B cells Bioethics Care and treatment Disease prevention Dosage and administration Drug dosages Drug therapy Drugs FDA approval Hepatitis Kidney diseases Lipids Lupus Medical research Medicine, Experimental Metabolism Mycophenolate mofetil Nonsteroidal anti-inflammatory drugs Pharmacy Prescribing Prescription drugs Rheumatic diseases Sociodemographics Systemic lupus erythematosus Transplantation of organs, tissues, etc Transplants & implants |
| title | Prescription Patterns of Mycophenolate Mofetil in a Group of Patients from Colombia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A24%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prescription%20Patterns%20of%20Mycophenolate%20Mofetil%20in%20a%20Group%20of%20Patients%20from%20Colombia&rft.jtitle=Healthcare%20(Basel)&rft.au=Machado-Duque,%20Manuel%20Enrique&rft.date=2024-11-07&rft.volume=12&rft.issue=22&rft.spage=2224&rft.pages=2224-&rft.issn=2227-9032&rft.eissn=2227-9032&rft_id=info:doi/10.3390/healthcare12222224&rft_dat=%3Cgale_pubme%3EA818200668%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3132952243&rft_id=info:pmid/39595422&rft_galeid=A818200668&rfr_iscdi=true |